chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chest pain, Pain
Clinical narrative: Chest pain; tightening across chest; Significant body aches and pain throughout the night; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 12:45 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included birth control. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified medication for birth control from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 19Apr2021 at 20:45, the patient experienced chest pain and tightening across chest, this was what came at onset of symptoms about 8 hours post vaccine. On 19Apr2021, the patient experienced significant body aches and pain throughout that night. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chest pain, tightening across chest, body aches and pain throughout the night was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Pain, Pyrexia
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 21-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 19Apr2021 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included fluticasone propionate (FLONASE), ethinylestradiol, levonorgestrel (JOLESSA), nadolol (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC) and sertraline (MANUFACTURER UNKNOWN); all for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 29Mar2021 at 09:00 (at the age of 21-years-old) as a single dose for COVID-19 immunisation. On 19Apr2021 at 20:00, the patient experienced fever, headache, aches and nausea. No therapeutic measures were taken as results of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, headache, aches, nausea was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Itching all over; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 02Apr2021 at 10:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included allergic rhinitis, hypothyroidism, osteopenia and had known allergy to penicillins. The patient received codeine (MANUFACTURER UNKNOWN) on an unknown date, for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205) via an unspecified route of administration in the left arm on 12Mar2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. On 06Apr2021, the patient experienced itching all over. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken and included diphenhydramine hydrochloride (BENADRYL) and alprazolam (XANAX). The clinical outcome of the event itching all over was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Facial pain, Headache, Hypoaesthesia oral, Hypokinesia
Clinical narrative: Injection arm unable to lift,, basically immobile; Numbness in mouth; Severe chills; Fever  2+ days,; Severe headache; Severe body ache; Lymph nodes in injection arm and neck swollen; Lymph nodes in injection arm and neck painful; Face twitch and painful days 3- 5; Face twitch and painful days 3- 5; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 10Apr2021 at 10:45 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patient had relevant medical history (unspecified) and allergies to medications, food, or other products (unspecified). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021 at 11:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. On 11Apr2021 at 02:45, the patient experienced severe chills, fever for 2 plus days, severe headache, severe body ache all lasting for 4 days. Lymph nodes in injected arm and neck was swollen and painful. The patient had face twitch and painful for 3-5 days. On 17Apr2021 day 7, the patient experienced numbness in mouth. On 20Apr2021 day 10, on the day of reporting the patient was unable to lift injected arm and was basically immobile. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe chills, fever, severe headache, severe body ache, lymph nodes in injected arm and neck swollen and painful, face twitch and painful was recovered with sequelae on an unknown date in Apr2021. The clinical outcome of the event numbness in mouth was unknown; while that of the event injected arm unable to lift and was basically immobile was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy, Muscle twitching, Pain, Pyrexia
Clinical narrative: Injection arm unable to lift,, basically immobile; Numbness in mouth; Severe chills; Fever  2+ days,; Severe headache; Severe body ache; Lymph nodes in injection arm and neck swollen; Lymph nodes in injection arm and neck painful; Face twitch and painful days 3- 5; Face twitch and painful days 3- 5; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 10Apr2021 at 10:45 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patient had relevant medical history (unspecified) and allergies to medications, food, or other products (unspecified). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021 at 11:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. On 11Apr2021 at 02:45, the patient experienced severe chills, fever for 2 plus days, severe headache, severe body ache all lasting for 4 days. Lymph nodes in injected arm and neck was swollen and painful. The patient had face twitch and painful for 3-5 days. On 17Apr2021 day 7, the patient experienced numbness in mouth. On 20Apr2021 day 10, on the day of reporting the patient was unable to lift injected arm and was basically immobile. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe chills, fever, severe headache, severe body ache, lymph nodes in injected arm and neck swollen and painful, face twitch and painful was recovered with sequelae on an unknown date in Apr2021. The clinical outcome of the event numbness in mouth was unknown; while that of the event injected arm unable to lift and was basically immobile was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Joint dislocation, Mass, Pain, Swelling
Clinical narrative: "i" was having mass body inflammation; causing subluxation of several of "my" joints/subluxation of shoulder; at the site bruising (bruise is still healing now), and pretty bad; Brain fog; "I" deal with chronic pain and my usual treatment couldn't touch how painful it was; A quarter-sized raised lump at the site; Shoulder where the vaccine was given was very swollen; Extreme exhaustion; Extreme pain in "my" joints, especially on the right side; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0151) via an unspecified route of administration in the right arm on 09Apr2021 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history included mast cell activation syndrome (MCAS) and joint hypermobility syndrome. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the left arm on 19Mar2021 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. On 09Apr2021, when the patient received the vaccine, it felt like the needle actually moved something aside in her shoulder. Later that evening (on 09Apr2021), the patient was having mass body inflammation causing subluxation of several of her joints, extreme exhaustion and extreme pain in joints, especially on the right side. The patient stated, she dealt with chronic pain and her usual treatment could not touch how painful it was. As per the patient, the shoulder where the vaccine was given was very swollen, including a quarter-sized raised lump at the site plus bruising (bruise was still healing), and pretty bad subluxation of her shoulder. The worst of the pain and swelling resolved in 1-2 days, but the fatigue and brain fog persisted for 5 days. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chronic pain and shoulder where the vaccine was given was very swollen was resolved on an unknown date in Apr2021, after the duration of in 1-2 days. The clinical outcome of the events fatigue and brain fog was resolved on an unknown date in Apr2021, persisted for approximately 5 days. The clinical outcome of the events mass body inflammation, subluxation of several of joints/subluxation of shoulder, a quarter-sized raised lump, extreme exhaustion, extreme pain in joints, especially on the right side was resolved on an unknown date in Apr2021. The clinical outcome of the event bruising was resolving (also reported as still healing).  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chest discomfort, Chills, Cough, Dizziness
Clinical narrative: Initial 12-24 hours: sore arm, tingling in arm; Initial 12-24 hours: sore arm, tingling in arm; Chills; Fatigue; Sore throat; Tight chest; Cough; Persistent headache; Joint pain; Foggy brain; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the left arm on 15Apr2021 at 14:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. On an unknown date in Apr2021, within initial 12-24 hours the patient experienced sore arm and tingling in arm. 3-5 days after vaccination the patient experienced chills, fatigue, sore throat, tight chest, cough, persistent headache, joint pain, foggy brain and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm, tingling in arm, chills, fatigue, sore throat, tight chest, cough, persistent headache, joint pain, foggy brain and dizziness was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Oropharyngeal pain, Pain in extremity
Clinical narrative: Initial 12-24 hours: sore arm, tingling in arm; Initial 12-24 hours: sore arm, tingling in arm; Chills; Fatigue; Sore throat; Tight chest; Cough; Persistent headache; Joint pain; Foggy brain; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the left arm on 15Apr2021 at 14:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. On an unknown date in Apr2021, within initial 12-24 hours the patient experienced sore arm and tingling in arm. 3-5 days after vaccination the patient experienced chills, fatigue, sore throat, tight chest, cough, persistent headache, joint pain, foggy brain and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm, tingling in arm, chills, fatigue, sore throat, tight chest, cough, persistent headache, joint pain, foggy brain and dizziness was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: Initial 12-24 hours: sore arm, tingling in arm; Initial 12-24 hours: sore arm, tingling in arm; Chills; Fatigue; Sore throat; Tight chest; Cough; Persistent headache; Joint pain; Foggy brain; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP6955) via an unspecified route of administration in the left arm on 15Apr2021 at 14:00 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. On an unknown date in Apr2021, within initial 12-24 hours the patient experienced sore arm and tingling in arm. 3-5 days after vaccination the patient experienced chills, fatigue, sore throat, tight chest, cough, persistent headache, joint pain, foggy brain and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore arm, tingling in arm, chills, fatigue, sore throat, tight chest, cough, persistent headache, joint pain, foggy brain and dizziness was resolving at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Dyspnoea, Faeces soft, Fatigue
Clinical narrative: Severe congestion; swelling in feet arms legs and hands; headache; Extreme fatigue; Short of breath; Body soreness; Irritability; Soft stools; Loss of taste; Loss of smell; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (COMIRNATY; Lot Number: ER8737) via an unspecified route of administration in the left arm on 03Apr2021 at 15:45 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included congestive heart failure, hypertension, hypothyroidism, narcolepsy, musculoskeletal disorder, arthritis and sciatica. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included metoprolol succinate (METOPROLOL), hydralazine hydrochloride (HYDRALAZINE), losartan (MANUFACTURER UNKNOWN) and levothyroxine sodium (LEVOTHYROXIN); all from an unknown date for unknown indication and unknown if ongoing. The patient previously received morphine sulfate (MORPHINE), codeine (MANUFACTURER UNKNOWN) and metronidazole (FLAGYL) and experienced drug allergy. On 06Apr2021, the patient experienced severe congestion, swelling in feet arms legs and hands, headache, extreme fatigue, short of breath, body soreness, and irritability, and soft stools, loss of taste and smell. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events congestion, swelling in feet arms legs and hands, headache, extreme fatigue, short of breath, body soreness, irritability, soft stools, loss of taste and smell was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Irritability, Nasal congestion, Pain, Peripheral swelling
Clinical narrative: Severe congestion; swelling in feet arms legs and hands; headache; Extreme fatigue; Short of breath; Body soreness; Irritability; Soft stools; Loss of taste; Loss of smell; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (COMIRNATY; Lot Number: ER8737) via an unspecified route of administration in the left arm on 03Apr2021 at 15:45 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included congestive heart failure, hypertension, hypothyroidism, narcolepsy, musculoskeletal disorder, arthritis and sciatica. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included metoprolol succinate (METOPROLOL), hydralazine hydrochloride (HYDRALAZINE), losartan (MANUFACTURER UNKNOWN) and levothyroxine sodium (LEVOTHYROXIN); all from an unknown date for unknown indication and unknown if ongoing. The patient previously received morphine sulfate (MORPHINE), codeine (MANUFACTURER UNKNOWN) and metronidazole (FLAGYL) and experienced drug allergy. On 06Apr2021, the patient experienced severe congestion, swelling in feet arms legs and hands, headache, extreme fatigue, short of breath, body soreness, and irritability, and soft stools, loss of taste and smell. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events congestion, swelling in feet arms legs and hands, headache, extreme fatigue, short of breath, body soreness, irritability, soft stools, loss of taste and smell was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Paraesthesia, Vaccination site pain
Clinical narrative: "I" started feeling a little more tired than usual; Slightly sore at the vaccine site; "My" right hand started to feel extremely tingly/ Every time "I" moved it or touched anything it felt like that area was full of needles; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 06Apr2021 at 08:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and known allergies to hops (beer). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. Concomitant medications included vitamin d nos (VITAMIN D); for an unknown indication from an unknown date and unknown if ongoing. On 06Apr2021 at 10:00, a little over an hour after her vaccination, the patient started feeling a little more tired than usual and slightly sore at the vaccine site. After a while she took a nap, sleeping on the side where she got the vaccine. When she woke up (which was sometime between 3-4 hours after the vaccine) her right hand started to feel extremely tingly. Every time she moved it or touched anything it felt like that area was full of needles. After about 10-15 mins though this went away. A couple hours later, the patient no longer felt tired, and though her arm was a little sore over the next day or so, it was nothing significant. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events feeling a little more tired than usual, right hand started to feel extremely tingly, every time she moved it or touched anything it felt like that area was full of needles was resolved on 06Apr2021, while that of slightly sore at the vaccine site was resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza, Rash
Clinical narrative: Severe flu symptoms; rash that spreading on both arms.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 12Apr2021 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Concomitant medications were not reported. It was unknown that prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 02:00, 36 hours after vaccination, the patient experienced severe flu symptoms including fever, sore throat, cough, extreme congestion. On an unknown date in Apr2021, 1 week after vaccination the patient experienced rash that spreading on both arms. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash that spreading on both arms and severe flu symptoms was not resolved at the time of report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Oxygen saturation, Oxygen saturation decreased
Clinical narrative: Around 4 was still feeling fatigue so took a nap 1.5 hour. Developed a fever (99.7F) around 6:30.; Yesterday around 1 pm I started feeling fatigued; Chilled, but no fever; My oxygen was 93-95, which is low for me usually 97-99.; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 12Apr2021 at 13:30(at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic back pain, fibromyalgia, osteoarthritis, osteopenia, myofascial syndrome, high blood pressure, basal cell carcinoma, spinal stenosis and known allergies to ACE inhibitors. The patient previously took tramadol hydrochloride (ULTRAM) and prednisone (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cyclobenzaprine (MANUFACTURER UNKNOWN) and amlodipine (MANUFACTURER UNKNOWN); both for an unknown indication from unknown date and unknown if ongoing. On 19Apr2021 at 13:00, the patient experienced started feeling fatigued and chilled, but no fever around 13:00 and she went for a 2-minute walk around 14:30. Around 16:00, the patient still felt fatigue so took a nap 1.5 hour.  She developed a fever (99.7F) around at 18:30.  She took 2 Tylenol.  The patient oxygen was 93-95, which was low for her usually 97-99.  Fever and oxygen returned to normal by 22:00.  The patient went to bed as normal and woke up fine the next morning. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of fever, chills and included treatment with two paracetamol (TYNELOL) . On 19Apr2021, the patient had body temperature test and the result was 99.7 degrees Fahrenheit. On 19Apr2021, the patient underwent Oxygen saturation test and the result was 93-95 (units unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever 99.7 Fahrenheit and oxygen was 93-95, which was low for her usually 97-99 was recovered on 19Apr2021 at 22:00 whereas the events feeling fatigued and chilled on an unknown date at Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Around 4 was still feeling fatigue so took a nap 1.5 hour. Developed a fever (99.7F) around 6:30.; Yesterday around 1 pm I started feeling fatigued; Chilled, but no fever; My oxygen was 93-95, which is low for me usually 97-99.; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 12Apr2021 at 13:30(at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic back pain, fibromyalgia, osteoarthritis, osteopenia, myofascial syndrome, high blood pressure, basal cell carcinoma, spinal stenosis and known allergies to ACE inhibitors. The patient previously took tramadol hydrochloride (ULTRAM) and prednisone (MANUFACTURER UNKNOWN) and experienced drug allergy. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included cyclobenzaprine (MANUFACTURER UNKNOWN) and amlodipine (MANUFACTURER UNKNOWN); both for an unknown indication from unknown date and unknown if ongoing. On 19Apr2021 at 13:00, the patient experienced started feeling fatigued and chilled, but no fever around 13:00 and she went for a 2-minute walk around 14:30. Around 16:00, the patient still felt fatigue so took a nap 1.5 hour.  She developed a fever (99.7F) around at 18:30.  She took 2 Tylenol.  The patient oxygen was 93-95, which was low for her usually 97-99.  Fever and oxygen returned to normal by 22:00.  The patient went to bed as normal and woke up fine the next morning. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of fever, chills and included treatment with two paracetamol (TYNELOL) . On 19Apr2021, the patient had body temperature test and the result was 99.7 degrees Fahrenheit. On 19Apr2021, the patient underwent Oxygen saturation test and the result was 93-95 (units unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever 99.7 Fahrenheit and oxygen was 93-95, which was low for her usually 97-99 was recovered on 19Apr2021 at 22:00 whereas the events feeling fatigued and chilled on an unknown date at Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure increased, Blood pressure measurement, Headache, Heart rate, Heart rate increased
Clinical narrative: Elevated heart rate (blood pressure and pulse); Elevated heart rate (blood pressure and pulse); Severe headache; Leg pain; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 11Apr2021 at 09:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included thyroid issues - only left lobe and known allergy to Sulfa. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Concomitant medications included ergocalciferol (VITAMIN D2) 50,000 IU and doxycycline (MANUFACTURER UNKNOWN); both for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12Apr2021 at 15:00, the patient experienced elevated heart rate (blood pressure and pulse), severe headache and leg pain. On the same day, the patient underwent blood pressure and the result was found to be elevated and also the patient underwent pulse rate and the result was found to be elevated. On 18Apr2021, the patient underwent nasal swab and the result was negative. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department visit or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events elevated heart rate (blood pressure and pulse), severe headache and leg pain was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, SARS-CoV-2 test
Clinical narrative: Elevated heart rate (blood pressure and pulse); Elevated heart rate (blood pressure and pulse); Severe headache; Leg pain; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 11Apr2021 at 09:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included thyroid issues - only left lobe and known allergy to Sulfa. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Concomitant medications included ergocalciferol (VITAMIN D2) 50,000 IU and doxycycline (MANUFACTURER UNKNOWN); both for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 12Apr2021 at 15:00, the patient experienced elevated heart rate (blood pressure and pulse), severe headache and leg pain. On the same day, the patient underwent blood pressure and the result was found to be elevated and also the patient underwent pulse rate and the result was found to be elevated. On 18Apr2021, the patient underwent nasal swab and the result was negative. The events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department visit or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events elevated heart rate (blood pressure and pulse), severe headache and leg pain was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Extreme exhaustion since the second dose vaccine.; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9810) via an unspecified route of administration in the left arm on 21Feb2021 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergy to penicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261) via an unspecified route of administration in the left arm on 22Jan2021 at 15:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Feb2021, since the second dose vaccine, the patient experienced extreme exhaustion. The patient did not know if this was related to the second dose of the vaccine but reported that it had occurred since that time. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event extreme exhaustion was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Cold sweat, Headache, Lymphadenopathy, Pyrexia
Clinical narrative: Swollen injection site; Sore injection site; Swollen lymph nodes in left armpit and left neck/clavicle; Cold sweats; Headache; Fever; chills; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0164) via an unspecified route of administration in the left arm on 17Apr2021 at 14:00 as a single dose for COVID-19 immunisation. Medical history included allergy to wasp/hornet stings and anomalous pulmonary veins. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamin D nos (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), fish oil (MANUFACTURER UNKNOWN), and probiotics (MANUFACTURER UNKNOWN) ) from an unknown date for an unknown indication and unknown if ongoing. The patient received other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8732) via an unspecified route of administration in the right arm on 27Mar2021 as a single dose for COVID-19 immunisation. On 18Apr2021 at 09:00, the patient experienced fever, chills, cold sweats, headache, sore injection site, swollen injection site, swollen lymph nodes in left armpit and left neck/clavicle. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, cold sweats, headache, sore injection site, swollen injection site, swollen lymph nodes in left armpit and left neck/clavicle was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site swelling
Clinical narrative: Swollen injection site; Sore injection site; Swollen lymph nodes in left armpit and left neck/clavicle; Cold sweats; Headache; Fever; chills; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0164) via an unspecified route of administration in the left arm on 17Apr2021 at 14:00 as a single dose for COVID-19 immunisation. Medical history included allergy to wasp/hornet stings and anomalous pulmonary veins. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamin D nos (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), fish oil (MANUFACTURER UNKNOWN), and probiotics (MANUFACTURER UNKNOWN) ) from an unknown date for an unknown indication and unknown if ongoing. The patient received other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8732) via an unspecified route of administration in the right arm on 27Mar2021 as a single dose for COVID-19 immunisation. On 18Apr2021 at 09:00, the patient experienced fever, chills, cold sweats, headache, sore injection site, swollen injection site, swollen lymph nodes in left armpit and left neck/clavicle. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, cold sweats, headache, sore injection site, swollen injection site, swollen lymph nodes in left armpit and left neck/clavicle was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Cough, Headache, Nasal congestion, Nausea
Clinical narrative: Nausea; Vomiting; Congestion; Low energy; Headache; Cough; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the right arm on 13Apr2021 at 15:30 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. Medical history included thyroid condition and iron deficiency anemia. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. On 15Apr2021 at 12:00, the patient experienced nausea, vomiting, congestion, low energy, headache and cough. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, vomiting, congestion, low energy, headache and cough were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Nausea; Vomiting; Congestion; Low energy; Headache; Cough; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in the right arm on 13Apr2021 at 15:30 (at the age of 49-year-old) as a single dose for COVID-19 immunisation. Medical history included thyroid condition and iron deficiency anemia. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. On 15Apr2021 at 12:00, the patient experienced nausea, vomiting, congestion, low energy, headache and cough. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, vomiting, congestion, low energy, headache and cough were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Lymphadenopathy, Nausea
Clinical narrative: Severely swollen lymph nodes, particularly clavicle lymph node on left side is swollen over collar bone; nausea; light headed; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 15Apr2021 at 09:45 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included pernicious anemia, mal rotation and asthma. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included ethinylestradiol/levonorgestrel (SEASONIQUE), omeprazole (MANUFACTURER UNKNOWN), cyanocobalamin (B-12) and vitamins nos (DAILY VITAMINS); all for unknown indication from unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 24Mar2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation and received metoclopramide (REGLAN) on an unknown date for an unknown indication and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 16Apr2021, the patient experienced severely swollen lymph nodes, particularly clavicle lymph node on left side is swollen over collar bone, nausea and light headed. The events resulted in doctor or other healthcare professional office/clinic visit. It was unknown if patient received any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severely swollen lymph nodes, particularly clavicle lymph node on left side is swollen over collar bone, nausea and light headed was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Disease recurrence, Urticaria
Clinical narrative: Hives; Aprrox 1-2 weeks after 2nd vaccination hives broke out.; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EI3302) via an unspecified route of administration on the right arm on an unspecified date in Jan2021 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included thyroid disorder and autoimmune hives. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not have known allergies. Concomitant medications included thyroid medications (unspecified). The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Feb2021, the patient experienced hives. It was reported that the patient had chronic urticaria but not had hives for 6 years. Approximately 1-2 weeks after second vaccination hives broke out. She still had hives in April. The event did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the event which included numerous treatments. The clinical outcome of the event hives was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.